Will IREN co-CEOs sell >$20M in additional stock by June 30, 2026?

The established pattern (Dec 2023: $9.8M combined; Sep 2025: $115M combined) shows escalating selling behavior. However, there are key differences for H1 2026: (1) IREN's stock price has declined significantly from the $33 September 2025 level, reducing the incentive to sell at lower prices; (2) the critical execution period (Sweetwater deployment, Microsoft revenue start) makes large insider sales particularly damaging optically; (3) no new RSU grants have been disclosed that would create the grant-and-sell trigger. The $20M threshold is relatively modest — it could be crossed with a single 500K-share sale at current prices. The behavioral pattern suggests selling will resume eventually, but timing is uncertain and price levels matter.

The Roberts brothers have shown a consistent pattern of discretionary selling without 10b5-1 plans. They retain ~14M shares each, providing ample inventory. Historical pattern shows selling into price strength — if IREN stock recovers on positive Sweetwater or Microsoft news, selling becomes more likely. The H1 2026 period (January-June) is 6 months, providing multiple windows outside blackout periods. However, the lower stock price and heightened scrutiny (our analysis, potential media attention) may deter selling. The probability is uncertain but above 25% given the established behavioral pattern.

Insider selling predictions are inherently low-confidence because they depend on personal financial decisions. The pattern is clearly established (twice in 2 years, escalating magnitude). But the current environment differs: (1) significantly lower stock price; (2) critical execution phase where insider sales signal lack of confidence; (3) potential SEC scrutiny of the September 2025 pattern; (4) upcoming earnings blackout periods limit windows. The probability is below one-third, reflecting that while the behavioral tendency exists, conditions are less favorable for selling in H1 2026.

The behavioral pattern strongly suggests the Roberts brothers will sell again. The question is timing and magnitude. H1 2026 provides enough time (6 months, multiple trading windows) for $20M in sales. The stock would need to be attractive for selling — if it rallies on positive news (Sweetwater progress, Microsoft revenue), selling becomes more likely. If it stagnates or declines, selling is less likely. Given the established pattern and ample share inventory, probability is around one-third.

The $20M threshold at depressed stock prices requires selling roughly 2-3M shares (depending on price). The Roberts brothers have each sold 2M shares in a single event before, so the magnitude is achievable. However, selling at current prices means accepting significantly less per share than September 2025. Personal financial needs or diversification goals could still drive sales, but the reduced incentive from lower prices is meaningful. Weighted below 30%.

The key variable is whether IREN's stock price recovers in H1 2026. If positive catalysts (Sweetwater progress, Q3 FY26 results showing AI revenue growth) push the stock higher, the probability of insider selling increases significantly — the pattern has been to sell into strength. If the stock remains depressed, selling is less likely. Given uncertainty about the stock trajectory, the probability centers around 30% reflecting the base rate of established selling behavior weighted against unfavorable current conditions.

Established grant-and-sell pattern. But stock price decline reduces incentive. No new RSU grants to trigger the pattern. 6-month window is sufficient. Probability around 28% reflecting behavioral tendency vs. unfavorable conditions.

Insider selling at significantly lower stock prices after $115M haul in September 2025 seems less likely. The Roberts brothers may have satisfied liquidity needs with the September sales. No new RSU grants as triggers. Heightened scrutiny deters discretionary sales. Below 25%.

The pattern exists but conditions are different. Lower stock price, no new grants, critical execution phase. The $20M threshold could be crossed with modest selling if the stock recovers. But base case is no significant selling in H1 2026 at current price levels. Probability around 25%.